Evidence map›Paper›PMID 41726695›Full record

ArticleACS omega2026

Significant Activity of Pytren-2Q, a 2‑Quinoline Polyamine Compound, against High-Concern Human Pathogenic Fungi.

Mario Inclán, Maria Paz Clares, Eduardo Álvarez-Duarte, Fabiola Fernández-Silva, Valentina Salas, Josep Guarro, Javier U Chicote, Begoña Verdejo, Estefanía Delgado-Pinar, Enrique García-España and 2 more

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mario InclánMolecular Science Institute, Universitat de València, C/Catedrático José Beltrán 2, 46980 Paterna, Spain.ORCID https://orcid.org/0000-0003-0585-8842
Maria Paz ClaresMolecular Science Institute, Universitat de València, C/Catedrático José Beltrán 2, 46980 Paterna, Spain.
Eduardo Álvarez-DuarteLaboratorio Micología, ICBM-F. de Medicina, Universidad de Chile, 1025000 Santiago, Santiago Metropolitan Region, Chile.
Fabiola Fernández-SilvaInstituto Microbiología Clínica, Facultad de Medicina, Universidad Austral de Chile, Independencia 631, 5110566 Valdivia, Chile.
Valentina SalasMycology Laboratory, Biomedical Department, Public Health Institute of Chile, Av. Marathon 1000, 7780050 Santiago, Chile.
Josep GuarroUnitat de Microbiologia, Departament de Ciències Mèdiques Bàsiques, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili and Institut d'Investigació Sanitària Pere Virgili (IISPV), Carrer Sant Llorenç, 21, Reus, 43201 Tarragona, Spain.
Javier U ChicoteDepartament de Medicina i Cirurgia, Institut d'Investigació Sanitària Pere Virgili (IISPV), Servei Anatomia Patològica, Hospital Universitari Joan XXIII Universitat Rovira i Virgili (URV), Mallafré Guasch, 4, 43007 Tarragona, Spain.
Begoña VerdejoMolecular Science Institute, Universitat de València, C/Catedrático José Beltrán 2, 46980 Paterna, Spain.ORCID https://orcid.org/0000-0003-3022-1835
Estefanía Delgado-PinarMolecular Science Institute, Universitat de València, C/Catedrático José Beltrán 2, 46980 Paterna, Spain.
Enrique García-EspañaMolecular Science Institute, Universitat de València, C/Catedrático José Beltrán 2, 46980 Paterna, Spain.ORCID https://orcid.org/0000-0002-4601-6505
Antonio García-EspañaDepartamento de Bioquímica y Biología Molecular, Universitat de Valencia, Carrer del Dr. Moliner, 50, 46100 Burjassot, Spain.
Enrique CalvoDepartment of Biochemistry and Biotechnology; Institute of Health Research Pere Virgili (IISPV); Center of Environmental, Food and Toxicological Technology (TecnATox), Universitat Rovira i Virgili, C/Marcel·lí Domingo 1, 43007 Tarragona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In view of the worldwide expansion of life-threatening invasive fungal diseases (IFDs) and fungal drug resistance, new antifungal drugs are urgently needed. To guide research and public health policies, the World Health Organization (WHO) specified 19 priority-concern human mold and yeast pathogens associated with serious risk of mortality or morbidity. We assessed the

Identifiers

PMID41726695
PMCPMC12917647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.